Sun Pharmaceutical Industries Limited (Sun Pharma) is India’s largest pharmaceutical company and one of the world’s leading specialty pharmaceutical organisations. With operations across 100+ countries, the company manufactures and markets specialty medicines, branded generics, generic formulations, consumer healthcare products, and Active Pharmaceutical Ingredients (APIs). Backed by 40 manufacturing facilities, 6 global R&D centres, and a workforce of over 43,000 employees, Sun Pharma has established a diversified global pharmaceutical business that serves both developed and emerging healthcare markets.
FY2024-25 marked another year of strong growth as the company strengthened its Specialty medicines portfolio through acquisitions, licensing agreements, and new product approvals while continuing to invest in research and development, manufacturing excellence, digital transformation, and sustainability. At the same time, the company operated in a rapidly evolving pharmaceutical landscape characterised by changing regulations, healthcare reforms, technological innovation, geopolitical uncertainty, and increasing demand for affordable healthcare.
A PESTEL analysis helps evaluate the external macro-environmental factors influencing Sun Pharma’s strategy, competitive position, and long-term growth prospects.
Sun Pharma Business Model in 2026: How Sun Pharmaceutical Makes Money
Political Factors
1. Government Healthcare Policies
Healthcare policies, medicine pricing regulations, reimbursement frameworks, and public healthcare programmes across different countries directly influence demand, market access, and commercial opportunities for Sun Pharma’s products.
2. Support for Pharmaceutical Manufacturing
Government initiatives such as India’s Production Linked Incentive (PLI) scheme and broader support for domestic pharmaceutical manufacturing encourage investment, strengthen local production capabilities, and improve export competitiveness.
3. Geopolitical Uncertainty
Management identifies geopolitical developments, trade tensions, tariffs, and changing global supply chains as important risks that may affect sourcing, manufacturing, medicine availability, and international operations.
4. Healthcare Access Initiatives
Governments across emerging markets continue investing in healthcare infrastructure, insurance coverage, and medicine accessibility, creating long-term growth opportunities for affordable branded generics and generic medicines.
5. International Trade Policies
Operating across more than 100 countries requires Sun Pharma to continuously adapt to changing import regulations, trade agreements, export controls, and country-specific pharmaceutical policies.
Sun Pharma Business Strategy in 2026
Economic Factors
1. Growth in Global Pharmaceutical Spending
Global pharmaceutical spending is projected to exceed US$2.3 trillion by 2028, supported by ageing populations, increasing chronic diseases, specialty medicines, and rising healthcare expenditure, creating favourable long-term demand for Sun Pharma’s products.
2. Rising Demand in Emerging Markets
India, Latin America, Southeast Asia, and other emerging markets continue experiencing rising healthcare spending, improving affordability, and expanding access to medicines, supporting long-term revenue growth.
3. Pricing Pressure
Healthcare systems worldwide continue emphasising affordability, generics, biosimilars, and value-based pricing, creating ongoing pressure on pharmaceutical pricing and profitability, particularly in generic medicines.
4. Currency and Global Operations
With nearly two-thirds of revenue generated outside India, exchange rate fluctuations, inflation, and global economic conditions influence Sun Pharma’s financial performance and competitiveness.
5. Healthcare Budget Constraints
Governments and healthcare payers continue implementing cost-control measures, reimbursement reforms, and procurement efficiencies, affecting market access and pricing strategies across developed markets.
Sun Pharma SWOT Analysis in 2026
Social Factors
1. Ageing Population
Increasing life expectancy and ageing populations worldwide are driving higher demand for medicines targeting chronic diseases, specialty therapies, and long-term healthcare management.
2. Rising Burden of Chronic Diseases
Growing prevalence of cardiovascular diseases, diabetes, oncology, autoimmune disorders, dermatological conditions, and other chronic illnesses continues expanding demand for Sun Pharma’s therapeutic portfolio.
3. Growing Healthcare Awareness
Improving healthcare awareness, preventive care, better diagnosis, and expanding healthcare infrastructure are increasing medicine consumption across both developed and emerging markets.
4. Consumer Shift Towards Self-Care
The growing adoption of over-the-counter medicines, wellness products, vitamins, and preventive healthcare supports expansion of Sun Pharma’s consumer healthcare business.
5. Talent and Workforce Development
Sun Pharma continues investing in attracting, retaining, and developing a diverse global workforce while strengthening leadership capabilities, scientific expertise, and organisational culture to support long-term innovation.
Technological Factors
1. Research and Development
Sun Pharma invested Rs. 3,248 crore (6.2% of sales) in research and development during FY2024-25, focusing on specialty medicines, differentiated formulations, complex generics, and innovative therapies.
2. Artificial Intelligence and Digital Transformation
The pharmaceutical industry is increasingly adopting Artificial Intelligence, advanced analytics, digital health platforms, and machine learning to improve drug discovery, clinical trials, manufacturing, supply chain management, and patient engagement. Sun Pharma continues strengthening its digital capabilities across business operations.
3. Clinical Development and Innovation
The company continues expanding its pipeline through clinical trials, regulatory approvals, acquisitions, and licensing agreements, strengthening its position in high-value specialty medicines.
4. Manufacturing Technologies
Advanced manufacturing processes, automation, quality systems, and digital production technologies help improve operational efficiency, product quality, and regulatory compliance across Sun Pharma’s global manufacturing network.
5. Specialty Medicine Innovation
Rapid scientific advances in biologics, immunotherapy, oncology, dermatology, ophthalmology, and precision medicine create long-term innovation opportunities while requiring sustained investment in research and clinical development.
Environmental Factors
1. Climate Change Initiatives
Sun Pharma continues integrating sustainability into its long-term business strategy by improving energy efficiency, reducing emissions, and strengthening climate resilience across its global operations.
2. Renewable Energy and Energy Efficiency
The company focuses on increasing renewable energy usage while improving manufacturing efficiency to reduce energy consumption and environmental impact.
3. Water Stewardship
Water conservation remains a strategic priority through efficient water management, conservation initiatives, and responsible resource utilisation across manufacturing facilities.
4. Sustainable Waste Management
Sun Pharma continues strengthening waste management practices, resource efficiency, and environmentally responsible manufacturing processes as part of its broader ESG commitments.
5. ESG Integration
The company integrates environmental, social, and governance (ESG) principles into its business strategy. Its inclusion in the S&P Global Sustainability Yearbook 2025 reflects global recognition of its sustainability performance.
Legal Factors
1. Pharmaceutical Regulatory Compliance
Operating across more than 100 countries requires compliance with diverse pharmaceutical regulations, manufacturing standards, product approvals, and quality systems enforced by agencies such as the US FDA and other global regulators.
2. Manufacturing Quality Standards
Maintaining compliance with global Current Good Manufacturing Practices (cGMP) remains critical for uninterrupted production, exports, and regulatory approvals. The company continues implementing corrective actions at facilities under US FDA observations.
3. Intellectual Property Protection
Sun Pharma’s growing Specialty business depends on patents, licensing agreements, regulatory exclusivity, and intellectual property protection to commercialise innovative therapies and generate long-term returns.
4. Corporate Governance Requirements
The company maintains a comprehensive governance framework focused on ethical conduct, transparency, compliance, and accountability while adhering to regulatory requirements across global markets.
5. Product Safety and Pharmacovigilance
As a global pharmaceutical manufacturer, Sun Pharma must comply with strict pharmacovigilance, patient safety, product quality, clinical trial, and post-market surveillance regulations to ensure medicine safety throughout the product lifecycle.
Source: Sun Pharma Annual Report 2024-25
